1307683-81-3 Usage
Uses
Used in Pharmaceutical Industry:
1-Benzyl-3-azetidinaMine 2HCl is used as a building block for the synthesis of various pharmaceuticals and organic compounds, contributing to the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
1-Benzyl-3-azetidinaMine 2HCl is used as a research chemical in the field of medicinal chemistry, aiding in the discovery and optimization of novel drug candidates.
Used in Neurodegenerative Disorder Treatment:
1-Benzyl-3-azetidinaMine 2HCl is used as a dopamine receptor agonist for the potential treatment of Parkinson's disease and other neurodegenerative disorders, offering a promising therapeutic approach for these conditions.
Used in Drug Development:
The hydrochloride salt form of 1-Benzyl-3-azetidinaMine is utilized in drug development due to its high solubility and stability, facilitating its incorporation into pharmaceutical formulations and enhancing its suitability for various applications in the industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1307683-81-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,7,6,8 and 3 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1307683-81:
(9*1)+(8*3)+(7*0)+(6*7)+(5*6)+(4*8)+(3*3)+(2*8)+(1*1)=163
163 % 10 = 3
So 1307683-81-3 is a valid CAS Registry Number.
1307683-81-3Relevant academic research and scientific papers
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 00500, (2016/01/12)
Described herein are compounds of Formula (I)-(XIII), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
SUBSTITUTED AMINO HETEROCYCLES USEFUL AS HIV ANTAGONISTS
-
Page/Page column 69, (2011/06/16)
The present invention relates to compounds of Formula (I): wherein the variables are as defined in the specification. The present invention further relates to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular for the treatment or prevention of chemokine-mediated disorders such as HIV infection.
